Most idiopathic pulmonary fibrosis (IPF) lung transplant recipients (IPF-LTRs) have short telomere length (ST). Inherited mutations in telomere-related genes are associated with the development of T cell immunodeficiency. Despite this, IPF-LTRs with telomere-related rare variants are not protected from acute cellular rejection (ACR). We set out to determine the impact of both age and telomere length on the circulating T cell compartment and ACR burden of IPF-LTRs. We identified 106 IPF-LTRs who had telomere length testing using flowFISH (57 with short telomeres, 49 with long telomers) as well as a subset from both cohorts who had cryopreserved PBMC at least one timepoint, 6 months post-transplantation. Circulating T cells from before transplantation and at 6 and 12 months-post transplantation were analyzed using multiparameter flow cytometry to study phenotype and functional capacity and bulk T cell receptor sequencing was performed to study repertoire diversity. Linear regression was used to study the relationship of age and telomere length on early (within 1 year) and late (between 1 and 2 years) acute cellular rejection. IPF-LTRs with ST were found to have premature 'aging' of their circulating T cell compartment, with age-agnostic elevations in post-transplant terminal differentiation of CD8+ T cells, increased granzyme B positivity of both CD8+ and CD4+ T cells, upregulation of the exhaustion marker, CD57, and chemotactic protein CCR5, and enhanced T cell receptor clonal expansion. Additionally, we found a significant decline in early ACR burden with increasing age, but only in the ST cohort. IPF-LTRs with ST have premature 'aging' of their circulating T cell compartment post transplantation, and a clear age-related decline in ACR burden.
Background: With new variants challenging the effectiveness of preventive measures, we are beginning to recognize the reality that COVID-19 will continue to pose an endemic threat. The manifestations of COVID-19 in lung transplant recipients during index admission are poorly understood with very few cases reported in recent lung transplant recipients. Optimal management of immunosuppression and antiviral therapy in recent transplant recipients is challenging. Methods: We performed a retrospective analysis identifying lung transplant recipients at our institution who contracted COVID-19 in the immediate postoperative period (within index admission). In addition, we performed a systematic review from January 2020 to August 2023 identifying all publications on the PUBMED database regarding COVID-19 infection in lung transplant recipients during index admission. Results: We report four cases of COVID-19 pneumonia in lung transplant recipients in the immediate postoperative period and we describe the clinical course, treatment options, and immunosuppression changes to manage this unique clinical problem. All patients made a full recovery and were eventually discharged home. Within our review of the literature, the most prevalent presenting symptoms were cough, dyspnea, and fatigue. Six (75%) patients decreased or held their antimetabolite. The two most common treatments were monoclonal antibodies (38%) and remdesivir (63%). Conclusion: Although previous literature demonstrates that COVID-19 can be deadly in recent lung transplant recipients, rapid treatment with anti-viral therapy/immunotherapy, deescalating immunosuppression, and treatment of respiratory decompensation with Decadron was effective in our patients.
Background: Lung retransplantation is offered to select patients with chronic allograft dysfunction. Given the increased risk of morbidity and mortality conferred by retransplantation, post‐transplant function should be considered in the decision of who and when to list. The aim of this study is to identify predictors of post‐operative disability in patients undergoing lung retransplantation.Methods: Data were collected from the UNOS national dataset and included all patients who underwent lung retransplant from May 2005–March 2023. Pre‐ and post‐operative function was reported by the Karnofsky Performance Status (KPS) and patients were stratified based on their needs. Cumulative link mixed effects models identified associations between pre‐transplant variables and post‐transplant function.Results: A total of 1275 lung retransplant patients were included. After adjusting for between‐group differences, pre‐operative functional status was predictive of post‐transplant function; patients requiring Total Assistance (n = 740) were 74% more likely than No/Some Assistance patients (n = 535) to require more assistance in follow‐up (OR 1.74, 95% CI 1.13–2.68, p = .012). Estimated one year survival of Total Assistance patients is lower than No/Some Assistance Recipients (72% vs. 82%, CI 69%–75%; 79%–86%) but similar to overall re‐transplant survival (76%, CI 74%–79%).Conclusion: Both survival and regain of function in patients requiring Total Assistance prior to retransplant may be higher than previously reported. Pre‐operative functional status is predictive of post‐operative function and should weigh in the selection, timing and post‐operative care of patients considered for lung retransplantation.